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Abstract The objective of this
study was to investigate the long-
term efficacy and safety of botu-
linum toxin type-A (BoNT-A) for
refractory chronic tension-type
headache (CTTH). An open-label,
prospective study was carried out
in the Department of Neurology of
Kirikkale University on 28 patients
(8 males, 20 females), mean age
35.6 years, diagnosed with moder-
ate/severe CTTH refractory to pre-
ventive medications. Each patient
received BoNT-A injections once
in pericranial muscles. Efficacy
and safety data were analysed for
28 refractory CTTH patients who
were receiving concomitant
headache prophylactic medications
at baseline and during the study.
The main outcome parameters
were reduction of headache fre-
quency and intensity over 1 year.
Both parameters were significantly
decreased (p<0.05) by the end of
the study. Sixty-four percent of
patients reported complete
headache relief at the final visit,
compared to 7% CTTH persisted.
BoNT-A also resulted in signifi-
cant reductions in analgesic con-
sumption (p<0.05). Adverse effects
were transient and local. BoNT-A
was found to be an effective and
safe treatment for refractory CTTH
patients with concomitant
headache prophylactic medica-
tions, resulting in significant
reductions in headache frequency,
intensity and analgesic consump-
tion which persisted up to 1 year.
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Tension-type headaches affect the majority of men and
women at some time in their lives and it has a lifetime preva-
lence of up to 30% in the general population [1–6]. The clin-
ical, epidemiological and societal impact of TTH is substan-
tial, which was demonstrated in the results of a study of a
Danish population which reported 870 workdays lost per
1000 people as a consequence of TTH, compared to 270
workdays lost per 1000 people for migraine [7].
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Chronic tension-type headache (CTTH) is defined as the
occurrence of tension-type headaches at a frequency of ≥15
days per month and is less prevalent than episodic tension-
type headache [8]. However, CTTH usually evolves from the
episodic form and causes significant functional impairment
and morbidity [9]. Patients with CTTH exhibit poorer quali-
ty of life measures, slightly more depressive symptoms, sig-
nificantly stronger avoidance behaviour and greater impair-
ments in functioning and general well-being than patients
with episodic tension-type headache [10, 11].
Botulinum toxin type-A (BoNT-A) is a focally acting
neurotoxin produced by the anaerobic bacterium,
Clostridium botulinum, which acts by interfering with
acetylcholine release at the neuromuscular junction to induce
temporary, reversible paralysis of the target muscle.
Intramuscular injections can be administered to treat a vari-
ety of conditions such as dystonias, post-stroke spasticity,
severe axillary hyperhydrosis and migraine headaches. Due
to its ability to block the responses of autonomic and senso-
ry nerves, additional applications at the central level have
also been investigated (e.g., hyperlacrimation, sialorrhoea
and pain conditions unrelated to muscle spasm). Recent evi-
dence suggests that BoNT-A may reduce inflammatory pain
and have distinct antinociceptive activities through inhibi-
tion of the release of nociceptive mediators [12]. With spe-
cific reference to its role in the treatment of headaches, the
effectiveness of BoNT-A has been investigated in the treat-
ment of CTTH and migraine, although a full understanding
of its mechanism of action in headache continues to evolve
[13–15]. CTTH differs from episodic tension-type headache
in terms of frequency, lack of response to most treatment
options, medication overuse and quality of life reduction.
Treatment of CTTH is very difficult, with many patients fail-
ing to respond to preventive medications. Conventional
treatment options comprise analgesics and prophylactic
medications originally intended for conditions such as
depression and epilepsy. However, the use of such medica-
tions in patients with CTTH can be limited due to lack of
efficacy or unacceptable adverse effects.
The purpose of this prospective, open-label study was to
assess the long-term efficacy and safety of BoNT-A treat-
ment of refractory CTTH.
Materials and methods
Design
This study was designed to investigate the efficacy and safety of
BoNT-A treatment of refractory CTTH. It comprised a prospective,
open-label, one-year analysis of patients treated at the Department of
Neurology.
Patients
Patients diagnosed with CTTH according to the IHS classification who
were refractory to other headache medications were included in the
study. All patients had received prior unsuccessful preventative and
symptomatic treatments, and had been refractory to all other previous
forms of headache treatment, including analgesics, non-steroidal anti-
inflammatory drugs and various antidepressants. All patients had
failed at least three prior treatments. All selected patients had been suf-
fering from moderate or severe CTTH for a minimum of three years
and had experienced at least 20 headache days per month. Patients
with structural lesions of the brain, spine or other local or systemic dis-
eases causing headache were excluded by appropriate laboratory stud-
ies. Informed consent was obtained prior to enrolling in the study.
Treatment protocol and outcome measures
Patients who were enrolled into the study were required to provide a
detailed medical history and underwent full clinical examination
prior to initiation of BoNT-A treatment. No other acute medication
was administered for at least 24 h prior to baseline testing and injec-
tion of BoNT-A. BoNT-A was injected into the most affected (ten-
der) pericranial muscles (follow the pain injection procedure). The
safety of BoNT-A treatment was assessed throughout the study with
the conduct of laboratory tests [e.g. complete blood count (CBC)
and blood chemistries] and monitoring of any adverse events.
Patients were evaluated at baseline, and post-treatment at weeks
4 and 12, and then at one year. All patients were asked to keep a
headache diary and record the number of days they experienced
headaches over a period of one year and the number of days they
experienced headaches judged to be sufficiently severe enough to
impair or incapacitate their functional ability. Treatment with symp-
tomatic medication was allowed on an ‘as needed’ basis for treat-
ment of individual headaches during the study. Patients were permit-
ted to continue with established headache prophylactic medications
and the dose was stabilised more than 30 days prior to eligibility and
held constant during the course of the study. Efficacy and safety data
were analysed for the patients who were receiving concomitant
headache prophylactic medications at baseline and during the study.
The effectiveness of BoNT-A treatment was evaluated by
assessment of changes in headache frequency and intensity, as well
as analgesic use. Headache intensity was defined using a 10 point
rating scale [range: 0 (no pain) to 10 (worst pain imaginable)]. A
physician’s global response rating assessed improvement as com-
plete response, partial response or non-response.
Statistical analysis
Student’s t-test, paired t-test, chi square and McNemar tests were
used for statistical analysis. A p value of less than 0.05 was consid-
ered to be statistically significant.
Results
A total of 28 patients [8 males (28.6%), 20 females (71.4%)]
with a mean age of 35.6 years (range: 26–47 years) were
enrolled and completed the study. Patients suffered a mean
headache frequency of 24.9±2.9 days per month (range:
20–30 days per month), with a mean headache intensity of
7.25±1.2 according to the 10-point rating scale (range: 5–9).
Mean analgesic consumption comprised 21.7±3.6 tablets per
month (range: 15–27 tablets).
BoNT-A treatment
Patients were administered a mean dose of 59.5±12.1 U
BoNT-A (BOTOX®) diluted in 100 U/ml saline once. The
median dose was 50 U and the total dose range was 45–75 U.
All pericranial muscles according to the pain injection proce-
dure (frontalis, splenius capitis, trapezius, occipitalis and
temporalis muscles) were injected.
Headache frequency
As a result of BoNT-A treatment, headache frequency was
found to be significantly reduced from a mean of 24.9±2.9
days per month at baseline to 14.9±3.5 days per month by the
end of week 4 (p<0.05), 9.1±4.8 days per month at week 12
(p<0.05) and 5.1±7.5 days per month by the end of the first
year (p<0.05) (see Fig. 1). The differences in headache fre-
quency were statistically significant between weeks 4 and 12
and between week 12 and one year (p<0.05).
Headache intensity and analgesic consumption
As a result of BoNT-A treatment, headache intensity accord-
ing to the 10-point rating scale was found to be statistically
significantly reduced from a mean score of 7.25±1.2 at base-
line to 6.1±1.6 at week 4 (p<0.05), 2.4±3.4 at week 12
(p<0.05) and 2.3±3.3 by the end of one year (p<0.05) (see
Fig. 2). The difference in intensity scores was statistically
significant between weeks 4 and 12 (p<0.05). In addition,
the mean consumption of analgesics consumed per month
significantly declined throughout the course of the study
(see Fig. 3).
Degree of headache frequency relief after BoNT-A treatment
With respect to improvement in the frequency of headaches
based on the physician’s global response rating, complete or
partial response was experienced by the vast majority of
patients. At week 4, 93% of patients achieved partial response,
with only 7% of patients indicating having no response or a
worsening of their headache frequency. At week 12, 25% of
patients had complete response, 68% had a partial response
and only 7% were found to have no response or a worsening
of their condition. By the study endpoint at one-year post-
Fig. 1 Changes in the number of headache days per month follow-
ing BoNT-A treatment
Fig. 2 Changes in headache intensity following BoNT-A treatment
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Using paired t-tests:
*p<0.05 vs. baseline; †p<0.05 vs. week 4; ‡p<0.05 vs. week 12
Using paired t-tests:
*p<0.05 vs. baseline; †p<0.05 vs. week 4
treatment, 64% of patients had achieved complete response,
29% had partial response and only 7% had either no response
or a worsening of headache frequency (see Table 1 and Fig. 4).
Headache intensity also improved by the study endpoint in 21
of the 28 patients (75%), while three of the 28 patients (11%)
experienced no change and headache intensity increased in
four of 28 patients (14%) (Fig. 5).
Global outcomes
A decrease in the intensity of CTTH-associated symptoms
such as nausea, vomiting, photophobia, phonophobia, vertig-
inous symptoms and dizziness was observed in 14 of the 28
patients (50%), while 11 of the 28 patients (40%) experi-
enced no change and three of 28 patients (10%) reported an
increase in intensity of such symptoms. No differences in
response to BoNT A treatment were seen with respect to gen-
der or age.
Safety and tolerability
BoNT-A treatment was found to be well-tolerated with the
only reported treatment-related adverse event being mild,
local tenderness for a few hours due to injection administra-
tion in eight patients.
Discussion
The results of this open-label, prospective study in 28
patients with moderate or severe CTTH demonstrated that
BoNT-A is a well tolerated and effective treatment for CTTH
in patients refractory to prior treatment. BoNT-A was found
to significantly reduce the frequency and intensity of CTTH
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Fig. 3 Reductions in analgesic consumption following BoNT-A
treatment
Fig. 4 Overall response to BoNT-A treatment at study endpoint (1
year), as assessed by headache frequency
Fig. 5 Overall response to BoNT-A treatment at study endpoint (1
year), as assessed by headache intensity
Table 1 Extent of response after BoNT-A treatment
Week 4 Week 12 1 year
n (%) n (%) n (%)
Complete response 0 7 (25) 18 (64)
Partial response 26 (93) 19 (68) 8 (29)
No change or worse 2 (7) 2 (7) 2 (7)
Using paired t-tests: *p<0.05 vs. baseline
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for up to 1 year post-treatment. Up to 93% of patients treat-
ed with BoNT-A reported some improvement in their
headache symptoms and use of BoNT-A resulted in signifi-
cant reductions in analgesic consumption.
Both open and randomised, double-blind and placebo-
controlled studies were performed with patients suffering
from tension-type headache. Contradictory results for the
efficacy of botulinum toxin were found. Relja reported a sig-
nificant reduction in headache duration, pain intensity and
pain sensitivity in 10 patients and found a lasting effect in
long-term use over 15 months in 24 patients [16,17]. Ondo et
al. reported in chronic daily headache patients that headache-
free days had improved in the BoNT-A group from weeks 8
to 12 (p<0.05) [18]. In an open study, Schulte-Mattler et al.
reported in nine patients with refractory CTTH the product
of pain duration and pain intensity was significantly reduced
[19]. However, several randomised, double-blind, placebo-
controlled trials did not find any significant difference
between Botox and placebo [20-22]. Although Burch et al.
also could not show a significant difference in headache fre-
quency between treatment with Botox and placebo, there
was a significant decrease of pain intensity in the treatment
group with Botox compared with the control group [23].
Smuts et al., in 37 patients with tension-type headache,
reported that a trend toward decreased headache severity
over the 3 months was observed in the BoNT-A-treated
group. This improvement reached statistical significance at
month 3 relative to the pretreatment month. Similarly, the
number of headache-free days was reported to be greater at
month 3 than at baseline [12]. Relja reported a prospective,
randomised, double-blind trial of BoNT-A in 16 patients with
CTTH who were resistant to medication. All of the patients
showed reduced severity of headache, reduced pericranial
muscle tenderness and increased headache-free days during
BoNT-A treatment. It was reported that 94% of placebo
patients still had moderate-to-severe headaches after treat-
ment compared with only 25% (moderate only) in the BoNT-
A group (75% had no or mild headaches after treatment)
[24]. Besides these, Mennini et al. reported that 85% of
CTTH patients experienced at least some degree of pain
relief and reduced their use of analgesics after BoNT-A treat-
ment [25]. BoNT-A therapy was reported to be an efficacious
new therapeutic choice in the prophylaxis of CDH, especial-
ly for patients not responding to previous prophylactic treat-
ments [26].
Comparisons between this study and reported studies are
complicated by differences in study design (number of injec-
tion session), patient populations and the concomitant
headache prophylactic medications of this study. The
responses of CTTH patients to the medication, concomitant
prophylactic medication and only one injection session of
BoNT-A differ in our study from the others. Although there
were a number of studies evaluating the prophylactic effica-
cy of BoNT-A in CCTH, in this study patients were CTTH
who were refractory to the treatment and besides that they
were permitted to continue with established headache pro-
phylaxis medications. Although Mathew et al. conducted a
randomised, placebo-controlled study to examine the effect
of BoNT-A in CDH with concomitant headache prophylactic
medication, there were nine CTTH patients and the results of
these CTTH patients were not reported separately [27]. In
our study, the possible impact of prophylactic medication use
on the outcomes has not been underestimated. As the patients
were refractory to the prophylactic headache medications for
at least 3 months prior to medication of stable doses of pro-
phylactic headache medications for at least 3 months prior to
the initiation of BoNT-A treatment and during the study, it
was noticed that headache intensity and frequency decreased
in a significant number of the patients with one BoNT-A
injection session and concomitant prophylactic medication.
CTTH patients often have an insufficient response to pre-
ventative medications, which persuades them misuse and
abuse analgesics. This mean that the vicious cycle has to be
broken in order to make the medication as effective. As the
options are limited for CTTH patients who are already
refractory to first- and second-line medications, botulinum
toxin injection may help to break these vicious cycles.
During this study, headache frequency and intensity and
analgesic consumption were decreased significantly, indicat-
ing that the cycle had been broken. Nevertheless, it was sug-
gested that one single treatment session could be insufficient
to treat this chronic pain syndrome. However, our patients
were responsive to the medication for CTTH after one BTX
injection session.
There are thought to be several mechanisms that con-
tribute to the development of CTTH. Firstly, chronic neuro-
genic inflammation may lead to abnormal excitation of the
peripheral nociceptive afferent fibres, causing an accumula-
tion of pain-producing metabolites which sustains nocicep-
tive input and lead to central sensitisation. Secondly,
enhanced responsiveness of the trigeminal nucleus caudalis
neurons may lead to pain signal generation through
supraspinal facilitation. Patients may also have decreased
pain modulation and there may be a generation of sponta-
neous central pain. These factors may act individually or in
combination to give rise to CTTH [28].
There are various theories explaining the proposed effi-
cacy of BoNT-A in the treatment of headaches. This includes
a reduction of muscular hyperactivity through disruption of
cholinergic innervation and normalisation of excessive mus-
cle spindle activity. Preclinical in vitro and in vivo evidence
demonstrates that botulinum toxin blocks the secretion of a
variety of neurotransmitters such as glutamate, calcitonin
gene-related peptide and substance P from nociceptive fibres
and down-regulates immediate early gene expression.
BoNT-A has also been shown to inhibit central sensitisation
299
of central trigeminovascular neurons. The toxin blocks
peripheral sensitisation directly and central sensitisation
indirectly [29-33].
The limitations of this study are that it is open-label analy-
sis that is not placebo-controlled or blinded. Second, only
CTTH patients with very refractory headaches were included,
which can significantly underestimate the potential results of
the therapy in less recalcitrant patients. Third, subjects were
permitted to use concomitant headache prophylactic medica-
tion. Part of the benefits might, therefore, be due to headache
prophylactic medication, rather than BoNT-A efficacy alone.
However, we achieved the maximum benefit more than with
BTX alone or headache prophylactic medication.
The use of BoNT-A has several advantages over conven-
tional treatment options, such as reduced adverse effects and
improved patient compliance. The results of this study sug-
gest that BoNT-A may be considered as a potential treatment
for refractory CTTH with concomitant headache prophylac-
tic medication headache. Although this study demonstrates
interesting initial results, further methodologically rigorous
studies comprising large, long-term, prospective, ran-
domised clinical trials in the field of CTTH are required to
clarify the effectiveness in breaking the cycle of CTTH.
Acknowledgements Presented at the XI Congress of the
International Headache Society, Rome, Italy, 13–16 September
2003. This study was supported by an unrestricted grant from
Allergan Inc, Irvine, CA, USA.
References
1. Mueller L (2002) Tension-type, the
forgotten headache. How to recognize
this common but undertreated condi-
tion. Postgrad Med 111:25–26, 31–32,
37–38 
2. Schulman EA (2001) Overview of ten-
sion-type headache. Curr Pain
Headache Rep 5:454–462
3. Cheung RTF (2000) Prevalence of
migraine, tension-type headache, and
other headaches in Hong Kong.
Headache 40:473–479
4. Gobel H, Petersen-Braun M, Soyka D
(1994) The epidemiology of headache
in Germany: a nationwide survey of a
representative sample on the basis of
the headache classification of the
International Headache Society.
Cephalalgia 14:97–106
5. Pryse-Phillips W, Findlay H, Tugwell
P et al (1992) A Canadian population
survey on the clinical, epidemiologic
and societal impact of migraine and
tension-type headache. Can J Neurol
Sci 19:333–339
6. Rasmussen BK, Jensen R, Schroll M,
Olesen J (1991) Epidemiology of
headache in a general population - a
prevalence study. J Clin Epidemiol
44:1147–1157
7. Rasmussen BK, Jensen R, Olesen J
(1992) Impact of headache on sickness
absence and utilisation of medical ser-
vices: a Danish population study.
J Epidemiol Community Health
46:443–446
8. Schwartz BJ, Stewart WF, Simon D,
Lipton RB (1998) Epidemiology of
tension-type headache. JAMA
279:381–383
9. Jensen K, Norup M (1992)
Experimental pain in human muscle
induced by hypertonic saline, potassi-
um and acidity. Cephalalgia
12:101–106
10. Rollnik JD, Karst M, Fink M, Dengler
R (2001) Coping strategies in episodic
and chronic tension-type headache.
Headache 41:297–302 
11. Holroyd KA, Stensland M, Lipchik GL
et al (2000) Psychosocial correlates
and impact of chronic tension-type
headaches. Headache 40:3–16
12. Borodic GE, Acquadro M, Johnson EA
(2001) Botulinum toxin therapy for
pain and inflammatory disorders:
mechanisms and therapeutic effects.
Expert Opin Investig Drugs
10:1531–1544
13. Smuts JA, Baker MK, Smuts HM et al
(1999) Prophylactic treatment of
chronic tension-type headache using
botulinum toxin type A. Eur J Neurol 6
[Suppl 4]:99–102
14. Evers S, Vollmer-Haase J, Schwaag S
et al (2004) Botulinum toxin A in the




15. Silberstein S, Mathew N, Saper J,
Jenkins S, for the BOTOX® Migraine
Clinical Research Group (2000)
Botulinum toxin type A as a migraine
preventive treatment. Headache
40:445–450
16. Relja MA (1997) Treatment of tension-
type headache by local injection of
botulinum toxin. Eur J Neurol 4[Suppl
2]:71–72
17. Relja MA (2000) Treatment of tension-
type headache with botulinum toxin:
1-year follow-up. Cephalalgia 20:336
18. Ondo WG, Vuong KD, Derman HS
(2004) Botulinum toxin A for chronic
daily headache: a randomized, place-
bo-controlled, parallel design study.
Cephalalgia 2004;24:60–65
19. Schulte-Mattler WJ, Wieser T, Zierz S
(1999) Treatment of tensiontype
headache with botulinum toxin: a pilot
study. Eur J Med Res 4:183–186
20. Schmitt WJ, Slowey E, Fravi N et al
(2001) Effect of botulinum toxin A
injections in the treatment of chronic
tension-type headache: a double blind,
placebo-controlled trial. Headache
41:658–664
21. Rollnik JD, Tanneberger O, Schubert
M et al (2000) Treatment of tension-




22. Silberstein SD, Göbel H, Jensen R et al
(2006) Botulinum toxin type A in the
prophylactic treatment of chronic ten-




23. Burch CM, Kokoska MS, Glaser DA,
Hollenbeak CS (2001) Treatment of
frontal tension headaches with botu-
linum toxin A. Cephalalgia
21:486–491
24. Relja MA, Telarovic S. Botulinum
toxin in tension-type headache (2004)
J Neurol 251[Suppl]1/12–1/14
25. Mennini FS, Fioravanti L, Piasini L et
al (2004) A one-year retrospective eco-
nomic evaluation of botulinum toxin
type A treatment of chronic tension
headache. J Headache Pain 5:188–191
26.Farinelli I, Coloprisco G, De Filippis
S, Martelletti P (2006) Long-term ben-
efits of botulinum toxin type A
(BOTOX) in chronic daily headache: a
five-year long experience. J Headache
Pain 7:407–412
27. Mathew N, Frishberg BM, Gawel M et
al (2005) Botulinum toxin type A
(BOTOX®) for the prophylactic treat-
ment of chronic daily headache: a ran-
domized, double-blind, placebo-con-
trolled trial. Headache 45:293–307
28. Jensen R (2003) Peripheral and central
mechanisms in tension-type headache:
an update. Cephalalgia 23 [Suppl. 1]:
49–52
29. Aoki KR (2003) Evidence for antinoci-
ceptive activity of botulinum toxin
type a in pain management. Headache
43[Suppl 1]:9–15
30. Cui M, Khanijou S, Rubino J, Aoki KR
(2004) Subcutaneous administration of
botulinum toxin A reduces formalin-
induced pain. Pain 107:125–133
31. Durham PL, Cady R (2004) Regulation
of calcitonin gene-related peptide
secretion from trigeminal nerve cells
by botulinum toxin type A: implica-
tions for migraine therapy. Headache
44:35–42; discussion 42–43
32. Oshinsky ML, Pozo-Rosich P, Luo J et
al (2004) Botulinum toxin type A
blocks sensitization of neurons in the
trigeminal nucleus caudalis.
Cephalalgia 24:781
33. Mathew N (2006) The prophylactic
treatment of chronic daily headache.
Headache 46:1552–1564
